MX2023009722A - Composiciones y compuestos para co-suministro de uridina y cetoleucina. - Google Patents
Composiciones y compuestos para co-suministro de uridina y cetoleucina.Info
- Publication number
- MX2023009722A MX2023009722A MX2023009722A MX2023009722A MX2023009722A MX 2023009722 A MX2023009722 A MX 2023009722A MX 2023009722 A MX2023009722 A MX 2023009722A MX 2023009722 A MX2023009722 A MX 2023009722A MX 2023009722 A MX2023009722 A MX 2023009722A
- Authority
- MX
- Mexico
- Prior art keywords
- ketoleucine
- uridine
- compositions
- compounds
- delivery
- Prior art date
Links
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 title abstract 4
- 150000001875 compounds Chemical class 0.000 title abstract 3
- BKAJNAXTPSGJCU-UHFFFAOYSA-N 4-methyl-2-oxopentanoic acid Chemical compound CC(C)CC(=O)C(O)=O BKAJNAXTPSGJCU-UHFFFAOYSA-N 0.000 title abstract 2
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 title abstract 2
- 229940045145 uridine Drugs 0.000 title abstract 2
- 230000003292 diminished effect Effects 0.000 abstract 2
- 210000003205 muscle Anatomy 0.000 abstract 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/067—Pyrimidine radicals with ribosyl as the saccharide radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La invención se refiere a compuestos y composiciones que liberan tanto uridina como cetoleucina son útiles en el tratamiento de trastornos caracterizados por disminución de la fuerza muscular o disminución de la masa magra muscular. Uno de tales compuestos es la 5'-O-cetoleucil-2',3'-di-O-acetiluridina.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163151750P | 2021-02-21 | 2021-02-21 | |
| US202163151849P | 2021-02-22 | 2021-02-22 | |
| US202163228304P | 2021-08-02 | 2021-08-02 | |
| PCT/US2022/014874 WO2022177740A1 (en) | 2021-02-21 | 2022-02-02 | Compositions and compounds for co-delivery of uridine and ketoleucine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023009722A true MX2023009722A (es) | 2023-11-10 |
Family
ID=82931897
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023009722A MX2023009722A (es) | 2021-02-21 | 2022-02-02 | Composiciones y compuestos para co-suministro de uridina y cetoleucina. |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240158431A1 (es) |
| EP (1) | EP4294405A1 (es) |
| JP (1) | JP2024509083A (es) |
| AU (1) | AU2022222618A1 (es) |
| BR (1) | BR112023016735A2 (es) |
| CA (1) | CA3211454A1 (es) |
| IL (1) | IL305338A (es) |
| MX (1) | MX2023009722A (es) |
| WO (1) | WO2022177740A1 (es) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4408450B2 (ja) * | 1994-07-01 | 2010-02-03 | ウェルスタット セラピューティクス コーポレイション | 全身性炎症および炎症性肝炎の処置のためのピリミジンヌクレオチド前駆体 |
| US7915233B1 (en) * | 1998-08-31 | 2011-03-29 | Wellstat Therapeutics Corporation | Compositions and methods for treatment of mitochondrial diseases |
| CA2841748C (en) * | 2011-07-15 | 2021-06-15 | Nusirt Sciences, Inc. | Compositions and methods for modulating metabolic pathways |
| WO2017070445A1 (en) * | 2015-10-23 | 2017-04-27 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Methods of treatment of rhabdomyolysis |
-
2022
- 2022-02-02 AU AU2022222618A patent/AU2022222618A1/en active Pending
- 2022-02-02 JP JP2023551096A patent/JP2024509083A/ja active Pending
- 2022-02-02 BR BR112023016735A patent/BR112023016735A2/pt unknown
- 2022-02-02 IL IL305338A patent/IL305338A/en unknown
- 2022-02-02 MX MX2023009722A patent/MX2023009722A/es unknown
- 2022-02-02 US US18/547,053 patent/US20240158431A1/en active Pending
- 2022-02-02 WO PCT/US2022/014874 patent/WO2022177740A1/en active Application Filing
- 2022-02-02 EP EP22756697.3A patent/EP4294405A1/en active Pending
- 2022-02-02 CA CA3211454A patent/CA3211454A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024509083A (ja) | 2024-02-29 |
| EP4294405A1 (en) | 2023-12-27 |
| AU2022222618A1 (en) | 2023-09-28 |
| US20240158431A1 (en) | 2024-05-16 |
| IL305338A (en) | 2023-10-01 |
| BR112023016735A2 (pt) | 2023-10-31 |
| WO2022177740A1 (en) | 2022-08-25 |
| CA3211454A1 (en) | 2022-08-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021014728A (es) | Composiciones terapeuticas que comprenden compuestos n,n-dimetiltriptamina deuterada o parcialmente deuterada. | |
| CR20230310A (es) | Inhibidores de prmt5 | |
| MX2010002258A (es) | Compuestos terapeuticos de isoxazol. | |
| CR20220675A (es) | Análogos de nucleósido de 1´- ciano y usos de los mismos | |
| KR930000117A (ko) | 이미다졸 화합물, 이의 제조방법 및 용도 | |
| MX2021008241A (es) | Compuesto heterociclico y su uso. | |
| MX2020012369A (es) | Composición fungicida estabilizada. | |
| MY144622A (en) | Agents for preventing and treating disorders involving modulation of the ryr receptors | |
| TWI265931B (en) | Composition and method for inhibiting platelet aggregation | |
| MXPA05006573A (es) | Metodos para el tratamiento de dolor y dano traumatico usando benzamidas y composiciones que las contienen. | |
| TW200744586A (en) | Therapeutic compounds | |
| BR0314126A (pt) | Ligandos de amida acìclica e sulfonamida para o receptor de estrogênio | |
| TW200639159A (en) | Treatment of pain | |
| MX2023001298A (es) | Combinaciones para el tratamiento de cancer. | |
| MX2023009222A (es) | Inhibidores tricíclicos-amido-bicíclicos de prmt5. | |
| MX2021015854A (es) | Composiciones y métodos para tratar trastornos del snc. | |
| MX2022009043A (es) | Compuestos de sulfonimidamida como moduladores de nlrp3. | |
| MX2021010700A (es) | Compuestos utiles en la terapia del vih. | |
| MX2023006677A (es) | Composiciones para tratar la degeneracion macular seca relacionada con la edad (dme). | |
| MX2022006151A (es) | Derivados de 1,2,4-oxadiazol como agonistas del receptor hepatico x. | |
| MX2023009722A (es) | Composiciones y compuestos para co-suministro de uridina y cetoleucina. | |
| PH12019502083A1 (en) | Preparation containing at least fludioxonil and a mixture containing aureobasidium pullulans strains | |
| CR20230223A (es) | Composiciones farmacéuticas de un inhibidor de cinasa | |
| MX2022001429A (es) | Formulaciones que incluyen dihidrohonokiol. | |
| PH12020551117A1 (en) | Compositions for preventing or treating uveitis |